Spectrum Pharmaceuticals Inc (SPPI) Stock
SPPI is no longer traded. Spectrum Pharmaceuticals was delisted from the Nasdaq in July 2023.
Prices on this page are historical; the last trade was July 28, 2023 at $1.03.
Spectrum Pharmaceuticals stock price history
SPPI final trading statistics
- Final close
- $1.03
- Final trading day
- Jul 28, 2023
- Market cap at delisting
- $211.40M
- Shares outstanding
- 205.25M
- Final 52-week range
- $0.32 – $1.57
- Avg. volume (final 3 mo.)
- 1,652,735
- All-time high (split-adj.)
- $598.16 · Mar 2000
- All-time low (split-adj.)
- $0.32 · Dec 2022
- Return since IPO
- -99.2%
- Beta
- 2.14
- Book value / share
- $0.13
- Price / book
- 7.80
Spectrum Pharmaceuticals annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2022 | $10.11M | -$78.1M | -$0.42 |
| FY2021 | $59.00 | -$158.4M | -$1.04 |
| FY2020 | $10.7K | -$171.3M | -$1.30 |
| FY2019 | $22.61M | -$135.4M | -$1.08 |
| FY2018 | $109.33M | -$120.0M | -$0.84 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Spectrum Pharmaceuticals Inc
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts. As of July 31, 2023, Spectrum Pharmaceuticals, Inc. operates as a subsidiary of Assertio Holdings, Inc.
Spectrum Pharmaceuticals stock FAQ
What happened to Spectrum Pharmaceuticals stock?
Spectrum Pharmaceuticals stock was delisted from the Nasdaq. Its final close was $1.03 on July 28, 2023.
Is SPPI stock still trading?
No. SPPI was delisted from the Nasdaq in July 2023 and no longer trades on a U.S. exchange.
What was the last price of SPPI stock?
SPPI closed at $1.03 on its final trading day, July 28, 2023, for a market value of about $211.40M.
What were Spectrum Pharmaceuticals's revenue and earnings in its last full fiscal year?
Spectrum Pharmaceuticals reported revenue of $10.11M and net income of -$78.1M in fiscal 2022, its last full year as a public company.
When did Spectrum Pharmaceuticals go public?
Spectrum Pharmaceuticals Inc stock began trading on September 26, 1996.